Key facts
- Status: Acquired/Merged (Operating Subsidiary).
Leadership
- John UrquhartSenior Managing Director & Member of the Investment Committee
- Ryan P. DelaneyAnalyst
- Tatiana FabianAssociate
- ·Watchlist + deal alerts for HCRx
- ·The full record, as it builds
Funding rounds
No funding rounds for HCRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HCRx
Operator of an investment firm intended to invest in commercial-stage and near-commercial-stage biopharmaceutical assets. The company has expertise in royalty monetizations, private debt and corporate financing solutions, which present a significant opportunity, given that the biopharma royalties market is currently addressing only a small portion of total biopharma capital needs and manages approximately $3 billion in assets with a portfolio that spans over 10 therapeutic areas and over 55 products.
- Sector
- Financial Services
- HQ
- Stamford, CT, United States
- Employees
- 34
- Website
- hcrx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
HCRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HCRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HCRx in its N-PORT filings yet. We sweep new filings monthly.